Compare GSK plc (GSK) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Zscaler Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Zscaler Inc trades at $233.73 (market cap $35.35B). The key difference: GSK plc is far larger — about 2.6× Zscaler Inc's market cap, and GSK plc pays a 3.9% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Zscaler Inc for 41 Days on average.
| GSK | ZS | |
|---|---|---|
Market Cap | $91.88B | $35.35B |
Volume | 7,730,529 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $61.18 | $336.27 |
52-Week Low | $43.24 | $118.05 |
Typical Hold Time | 93 Days | 41 Days |
Enterprise Value | $111.88B | $33.73B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Zscaler (ZS) trades at $216.99, up 1.61% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -1.88% net margin. Recent quarters have consistently beaten EPS estimates, while analyst sentiment remains overwhelmingly positive with 79.63% buy ratings and a $222.83 consensus target.
ZS presents growth potential through cybersecurity demand and AI product expansion, but faces execution risks from leadership changes and competitive pressures. The stock trades at premium valuations (P/S 10.36) while still losing money, creating both opportunity and vulnerability if growth slows or margins don't improve as expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
